case_images: PMC10727514_01
case_images: Comparison of images during the initial diagnosis and the appearance of anemia. a Primary tumor at initial diagnosis on contrast-enhanced CT. b Primary tumor during anemia on contrast-enhanced CT. c Brain metastases at initial diagnosis on head MRI. d Brain metastases during anemia on head MRI. MRI, magnetic resonance imaging; CT, computed tomography.
case_images: cro-2023-0016-0001-535468_F01.jpg
case_images: PMC10727514_01_cro-2023-0016-0001-535468_F01.jpg
case_images: F1
case_images: Contrast-enhanced computed tomography and magnetic resonance imaging revealed no tumor progression (Fig. 1).
case_images: a Hematoxylin and eosin staining findings of bone marrow specimens. No erythroblast islands were observed. b Immunohistochemical staining findings of bone marrow specimens. Granulocytic cells (myeloperoxidase [MPO]-positive) and megakaryocytes (CD42b-positive) were observed; however, erythroblasts (glycophorin C-positive) were absent. These findings were consistent with PRCA.
case_images: cro-2023-0016-0001-535468_F02.jpg
case_images: PMC10727514_01_cro-2023-0016-0001-535468_F02.jpg
case_images: F2
case_images: Biopsy revealed the presence of granulocytes and megakaryocytes and only a few erythroblasts (Fig. 2a, b).
case_images: Transition of the hemoglobin level and course of treatment.
case_images: cro-2023-0016-0001-535468_F03.jpg
case_images: PMC10727514_01_cro-2023-0016-0001-535468_F03.jpg
case_images: F3
case_images: Subsequently, the dose was gradually reduced by 5 mg every 2 weeks; even after the reduction to 5 mg, the hemoglobin level did not decrease again, and the same dose has been continued since then (Fig. 3).